2. Academic Validation
  3. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV

  • Bioorg Med Chem Lett. 2013 May 15;23(10):2955-61. doi: 10.1016/j.bmcl.2013.03.047.
Mark J Mitton-Fry 1,  Steven J Brickner,  Judith C Hamel,  Lori Brennan,  Jeffrey M Casavant,  Michael Chen,  Tao Chen,  Xiaoyuan Ding,  James Driscoll,  Joel Hardink,  Thuy Hoang,  Erbing Hua,  Michael D Huband,  Meghan Maloney,  Anthony Marfat,  Sandra P McCurdy,  Dale McLeod,  Michael Plotkin,  Usa Reilly,  Shaughn Robinson,  John Schafer,  Richard M Shepard,  James F Smith,  Gregory G Stone,  Chakrapani Subramanyam,  Kwansik Yoon,  Wei Yuan,  Richard P Zaniewski,  Christopher Zook
Affiliations

Affiliation

  • 1 Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA. mjmitton@owu.edu
PMID: 23566517 DOI: 10.1016/j.bmcl.2013.03.047
Abstract

A structurally novel set of inhibitors of Bacterial type II topoisomerases with potent in vitro and in vivo Antibacterial activity was developed. Dual-targeting ability, hERG inhibition, and pharmacokinetic properties were also assessed.

Figures